The knockdown of advanced glycosylation end product-specific receptor (AGER), the receptor of S100A9, eradicates the NF-κB-mediated pro-tumorigenic effects of S100A9, suggesting that S100A9 controls the crosstalk between tumor cells and TAMs and could be a potential target for treating HCC patients [90,91]. The gene discussed is S100A9; the disease is neoplasm.